YAMAZAKI Etsuko

J-GLOBAL         Last updated: May 2, 2018 at 15:20
 
Avatar
Name
YAMAZAKI Etsuko
Affiliation
Yokohama City University
Section
Hospital
Job title
Associate Professor

Research Interests

 
 

Published Papers

 
Hyper-recovery of platelets after induction therapy is a predictor of relapse-free survival in acute myeloid leukemia.
YAMAZAKI Etsuko
Leukemia & Lymphoma   7 1-6   Jun 2016   [Refereed]

Misc

 
Leukemia Research      Jun 2015
© 2015 Elsevier Ltd. Useful prognostic markers for patients with diffuse large B cell lymphoma (DLBCL) have been reported. To identify which biomarker best predicts the prognosis of patients with DLBCL, we performed a retrospective study that incl...
[Rinshō ketsueki] The Japanese journal of clinical hematology   56 392-399   Apr 2015
We retrospectively analyzed, and herein discuss, the outcomes of and prognostic factors for 35 untreated multiple myeloma patients less than 65 years of age who received induction therapies with bortezomib (Bor) and dexamethasone (BD) for the purp...
Hematological Oncology   33 9-14   Jan 2015
© 2014 John Wiley & Sons, Ltd. Pirarubicin tetrahydropyranyl adriamycin (THP-ADR) is an analogue of doxorubicin. This agent exhibits activity against some doxorubicin-resistant cell lines. We performed a phase II study of biweekly THP-COP [50mg/m2...
Leukemia Research   39 582-585   Jan 2015
© 2015 Elsevier Ltd. Irradiation therapy alone is a standard strategy for limited-stage FL, leading to a 10-year progression-free survival (PFS) rate of 30-50%. However, we have been administering R-CHOP therapy alone to patients with limited-stag...